Treatment of severe proliferative lupus nephritis: the current state. Issue 9 (15th August 2003)

• Record Type: Journal Article
• Authors: Mok, C C; Wong, R W S; Lai, K N
• Is Part Of: Annals of the rheumatic diseases. Volume 62:Issue 9(2003)
• Page Start: 799
• Page End: 804
• Publication Date: 2003-08-15
• Subjects: cytotoxicity -- glomerulonephritis -- immunosuppressive drugs -- toxicities; AZA, azathioprine -- CSA, cyclosporin A -- CYC, cyclophosphamide -- DPGN, diffuse proliferative glomerulonephritis -- IVIg, intravenous immunoglobulin -- MMF, mycophenolate mofetil -- MP, methylprednisolone -- NIH, National Institutes of Health -- SLE, systemic lupus erythematosus; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.62.9.799
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Despite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered.